RADIANT

RecruitingPhase 2, PHASE3

Role of GLP1 RA Dulaglutide on Severe Intracranial Atherosclerosis

Role of Glucagon-like Peptide 1 Receptor Agonist (GLP1 RA) Dulaglutide on Cerebral Hemodynamics In Patients With Severe and symptomAtic steNosis of inTracranial Internal Carotid Artery or Middle Cerebral Artery With Impaired Cerebral Vasodilatory Reserve- an Open-label Randomised Clinical Trial (RADIANT)

Lead sponsor

National University of Singapore

Asset

Dulaglutide

Subcutaneous · GLP-1 agonist

Listed sites

Recruiting sites

Estimated enrollment

130

Study population

Cardiovascular disease, Stroke

Eligibility highlights

Primary endpoint

•Whether GLP1 RA (Dulaglutide) therapy would improveme cerebral vasodilatory

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07282041

Org study IDRADIANT01

Timeline

Milestones

Study first posted2025-12-15actual

Study start2025-12-17actual

Last update posted2025-12-23actual

Primary completion2030-12-01estimated

Study completion2030-12-01estimated

Assets

Investigational agents

Dulaglutide

Who this study enrolls

Cardiovascular diseaseStroke

Who can enroll

Minimum age21 Years

Maximum age80 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Adult patients aged 21 - 80 years old inclusive,

•Able to provide consent,

•Score 3 or less on the Modified Rankin Score (mRS),

•Patients with TIA or mild stroke with severe stenosis of intracranial ICA or MCA and impaired CVR within previous 3-months of acute stroke or TIA

Exclusion criteria

•Chronic kidney disease stage 5 (eGFR<15 mL/min) or on dialysis,

•Cancer diagnosed within past 3 years,

•Currently being planned for coronary or carotid artery revascularization,

•History of previous pancreatitis,

•History of medullary thyroid cancer,

•Atrial fibrillation,

•Any other condition likely to limit protocol compliance (judged by investigator).

•For diabetic patients, patients should not be on Sodium-glucose cotransporter 2 (SGLT2) inhibitor or pioglitazone during the duration of the study, unless these drugs can be stopped without affecting participants' medical condition. For those on Dipeptidyl peptidase-4 (DPP IV) inhibitor, this agent will be discontinued if the patient is randomised to the intervention group.

•Known allergies to Acetazolamide.

•Women who are pregnant or breastfeeding.

Endpoints (3)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Cardiovascular outcomes

Other (unclassified)

Cardiovascular outcomes

2 endpoints

Secondary/protocol endpoint

To evaluate the impact of Dulaglutide on recurrence of cerebral ischaemic event within 1 year.

Time frame:within 1year

Ischemic stroke

time to event, event

SNOMED 230690007

Secondary/protocol endpoint

To evaluate whether Dulaglutide would reduce MACE within 2 years

Time frame:within 2 years

3-point MACE

time to event, event

componentsCardiovascular death, Non-fatal MI, Non-fatal stroke

Other (unclassified)

1 endpoint

Primary/protocol endpoint/low confidence

To evaluate whether GLP1 RA (Dulaglutide) therapy would improveme cerebral vasodilatory reserve by at least 4 points in patients with severe stenosis of ICA or MCA

Time frame:within 1 year

threshold achievement, improvement

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 6, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.